Transfection Kit
This sits in the upper-middle of the Medical Equipment & Pharmaceuticals band — a substantial contract for the sector. Based on 9,456 valued Medical Equipment & Pharmaceuticals tenders in our corpus.
The Clinical Biotechnology Centre at the NHS Blood and Transplant is an MHRA licensed facility for the manufacture of investigational medical products such as advanced therapies and biotechnology products which includes plasmid DNA, viral vectors and therapeutic proteins.
The organisation intends to initiate a procurement process for the supply of advanced and cost-effective transfection reagents demonstrating optimal performance characteristics for the delivery of various nucleic acid formats into mammalian cells.
In the initial phase, transfection reagents are sought for the production of lentiviral and adeno-associated viral vectors utilizing packaging cell lines, and for a range of related research and clinical applications.
It is anticipated that these reagents also will be utilised for gene therapies and other therapeutic manufacturing or research purposes using DNA and RNA or other novel modalities requiring transfection.
The transfection reagent of choice must demonstrate the efficient and low-cytotoxic delivery of the following non-exhaustive list modalities such as plasmid DNA, synthetic DNA, enzymatically produced DNA, RNA and any other novel modalities.
The reagent must be of GMP quality and be compatible with HEK293 suspension and adherent cell culture systems for clinical grade manufacturing of gene therapy vectors.
Suitability to transfect cells in process intensified cell culture system is a critical requirement along with cell culture systems that utilise high cell density cultures.
Transfection reagent should be suitable to be used in scalable bioreactor systems.
What the supplier must deliver
The organisation intends to initiate a procurement
The organisation intends to initiate a procurement process for the supply of advanced and cost-effective transfection reagents demonstrating optimal performance characteristics for the delivery of various nucleic acid formats into mammalian cells.
The transfection reagent of choice must demonstrate
The transfection reagent of choice must demonstrate the efficient and low-cytotoxic delivery of the following non-exhaustive list modalities such as plasmid DNA, synthetic DNA, enzymatically produced DNA, RNA and any other novel modalities.
The reagent must be of GMP quality
The reagent must be of GMP quality and be compatible with HEK293 suspension and adherent cell culture systems for clinical grade manufacturing of gene therapy vectors.
Transfection reagent should be suitable to
Transfection reagent should be suitable to be used in scalable bioreactor systems.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at NHS Blood and Transplant, and generate a go-to-market strategy from their news, accounts and people.
The full intelligence dossier
Our agent reads NHS Blood and Transplant’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-0544f1
- Stage
- planning · Planning
- Source
- Find a Tender
- Buyer ref
- 030784-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
NHS Blood and Transplant’s tender network
Assembling the network…